Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Vaccinogen, Inc. (VGEN) Starts Presentation at 2015 Marcum MicroCap Conference

Vaccinogen is a cancer vaccine company that is clinically testing OncoVAX®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid tumors. The patented process leverages a patient’s own live tumor cells to launch a broad immune response against minimal residual disease. Vaccinogen believes that OncoVAX®, at an optimal dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence after surgical resection by addressing the diversity of cancer cells inherent to each patient’s tumor. Five clinical studies of OncoVAX® have been completed to date. Vaccinogen expects to begin enrolling patients in a pivotal phase 3b trial under an FDA Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) when adequate funding is obtained. For more information, visit the company’s website at www.vaccinogeninc.com.

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.